Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Pharmaceuticals Inc.

www.reatapharma.com

Latest From Reata Pharmaceuticals Inc.

Reata Expands Options For Bardoxolone With New CKD Data

Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.

Clinical Trials Research & Development

Pay Day For Reata As Bardoxolone Progresses For Kidney Disease In Japan

Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.

Japan Commercial

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.

Financing Business Strategies

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Reata Discovery Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Reata Pharmaceuticals Inc.
  • Senior Management
  • Warren Huff, Pres. & CEO
    Jason Wilson, VP, Strategy & CFO
    Colin Meyer, MD, VP Product Dev. & CMO
    Keith Ward, Chief Development Officer
    Bir C Dawn, VP, Chief Commercial Officer
  • Contact Info
  • Reata Pharmaceuticals Inc.
    Phone: (972) 865-2219
    2801 Gateway Dr., Ste. 150
    Irving, TX 75063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register